Valeant Pharmaceuticals Intl (NYSE:VRX)‘s stock had its “buy” rating reaffirmed by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Sunday, MarketBeat reports.
Several other equities analysts have also issued reports on the company. BMO Capital Markets reiterated a “buy” rating and issued a $285.00 price objective (up from $266.00) on shares of Valeant Pharmaceuticals Intl in a research note on Saturday. TD Securities increased their price target on Valeant Pharmaceuticals Intl from $280.00 to $300.00 and gave the stock a “buy” rating in a research report on Friday. Scotiabank reaffirmed a “sector outperform” rating and set a $310.00 price objective (up previously from $290.00) on shares of Valeant Pharmaceuticals Intl in a report on Friday. RBC Capital reissued a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, July 21st. Finally, BTIG Research initiated coverage on Valeant Pharmaceuticals Intl in a research note on Monday, July 20th. They set a “buy” rating and a $275.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $235.38.